<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7cff920d-64f6-4cb9-b482-94a6f30cb048"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">
         <content styleCode="bold">These highlights do not include all the information needed to use ENSACOVE safely and effectively. See full prescribing information for ENSACOVE.<br/>
         </content>
      </content>
      <br/>
      <content styleCode="bold">ENSACOVE<sup>TM</sup> (ensartinib) capsules, for oral use<br/>
      </content>
      <content styleCode="bold">
         <content styleCode="bold">Initial U.S. Approval: 2024</content>
      </content>
   </title>
   <effectiveTime value="20241226"/>
   <setId root="1e1b2f79-678a-472a-b924-66909c8a4b2e"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="033440609" root="1.3.6.1.4.1.519.1"/>
            <name>Xcovery Holdings, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="19664fcc-dec2-45e3-9690-9b5b030abddb"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241230"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="83076-1025" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ENSACOVE</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ensartinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2FR6VT1BQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ENSARTINIB HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="SMA5ZS5B22" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ENSARTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="83076-1025-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250430"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218171" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>opaque;body;cap</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">X396;25;mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="83076-1100" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ENSACOVE</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ensartinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2FR6VT1BQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ENSARTINIB HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="SMA5ZS5B22" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ENSARTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="I753WB2F1M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 5</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="83076-1100-6" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250430"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218171" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="blue" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>opaque;cap</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>opaque;body</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">X396;100;mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_9cedbd71-478e-49e9-8e01-1d453a8ab86a">
               <id root="be9b6db8-7c12-48b5-983b-7104455c6782"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.</paragraph>
               </text>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. (<linkHtml href="#LINK_9cedbd71-478e-49e9-8e01-1d453a8ab86a">1</linkHtml>, <linkHtml href="#LINK_cd9ce59f-05bb-40db-9d19-a17b745fa565">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8f555a37-6936-42bd-a5b5-8da119928076">
               <id root="8d03c50b-f8d8-457b-b115-965cb88a0252"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Select patients with ALK-positive locally advanced or metastatic NSCLC for treatment with ENSACOVE. (<linkHtml href="#LINK_cd9ce59f-05bb-40db-9d19-a17b745fa565">2.1</linkHtml>)</item>
                           <item>Prior to initiating ENSACOVE, evaluate liver function tests and fasting blood glucose. (<linkHtml href="#LINK_f37a8ee5-0834-4701-8152-a8754b5292b7">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Recommended dosage:</content> 225 mg orally once daily with or without food until disease progression or unacceptable toxicity. (<linkHtml href="#LINK_f37a8ee5-0834-4701-8152-a8754b5292b7">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_cd9ce59f-05bb-40db-9d19-a17b745fa565">
                     <id root="5c8e5b90-7d94-45d9-b8ce-b6638c315735"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Patient Selection</content>
                     </title>
                     <text>
                        <paragraph>Select patients for the treatment of locally advanced or metastatic NSCLC with ENSACOVE based on the presence of ALK rearrangement(s) in tumor specimens <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_8a440c67-f3a4-4218-b478-6d4bcb4a8480">14.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. An FDA-approved test to detect ALK rearrangements for selecting patients for treatment with ENSACOVE is not currently available.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e09e47a2-49e3-4e11-be14-178381de58a8">
                     <id root="909d8732-b2de-418b-93e2-c78dc1e08bf5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Recommended Testing and Advice Prior to Initiating ENSACOVE</content>
                     </title>
                     <text>
                        <paragraph>Prior to initiating ENSACOVE, evaluate liver function tests <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_fdaa6fa0-f9ab-4808-8873-59eab27ec660">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">)] </content>and fasting blood glucose <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_60153909-d092-4ebb-b7c1-a447d10276c2">5.5</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f37a8ee5-0834-4701-8152-a8754b5292b7">
                     <id root="ca1caa1c-5b87-4f75-90bf-fcd6ed67813b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Recommended Dosage</content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage of ENSACOVE is 225 mg orally once daily, with or without food <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>, until disease progression or unacceptable toxicity.</paragraph>
                        <paragraph>Swallow capsules whole, do not crush or chew. Do not open or dissolve the contents of the capsule. Take ENSACOVE at the same time each day.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Missed dose</content>
                        </paragraph>
                        <paragraph>If a dose is missed, then take the missed dose as soon as possible unless the next dose is due within 12 hours. Do not take 2 doses on the same day.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vomiting</content>
                        </paragraph>
                        <paragraph>If vomiting occurs after taking a dose, do not take an additional dose and take the next dose at its scheduled time.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_012c2eae-a161-4baa-bdd8-51c043d57771">
                     <id root="6d83084b-fd0a-4681-811f-1539bf44081f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.4 Dosage Modification for Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>The recommended dose reductions for adverse reactions are provided in Table 1.</paragraph>
                        <table width="387.6px">
                           <caption>Table 1: Recommended Dose Reductions for Adverse Reactions</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Dose Reduction</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Recommended Dose and Schedule</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">First</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">200 mg orally once daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Second</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">150 mg orally once daily</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Permanently discontinue ENSACOVE if patients are unable to tolerate 150 mg orally once daily.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Once the dose has been reduced for adverse reactions, do not subsequently increase the dose of ENSACOVE.</paragraph>
                        <paragraph> The recommended dosage modifications for the management of adverse reactions are provided in Table 2.</paragraph>
                        <table width="931.2px">
                           <caption>Table 2: Recommended ENSACOVE Dosage Modifications for Adverse Reactions</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Severity*</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">ENSACOVE Dose Modification and Management for Adverse Reactions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Interstitial Lung Disease (ILD)/Pneumonitis </content>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_921ae98f-0bfc-48a7-b789-d15f3d85ffea">5.1</linkHtml>)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any Grade</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">  Permanently discontinue ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Hepatotoxicity </content>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_fdaa6fa0-f9ab-4808-8873-59eab27ec660">5.2</linkHtml>)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 3 or 4 elevation (greater than 5 times ULN) of either ALT or AST with concurrent total bilirubin less than or equal to 2 times ULN</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold ENSACOVE until recovery to Grade ≤1 (≤3 times ULN) or to baseline.</item>
                                       <item>Resume ENSACOVE at reduced dose as per Table 1.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 2 to 4 elevation (greater than 3 times ULN) of either ALT or AST with concurrent total bilirubin elevation greater than 2 times ULN in the absence of cholestasis or hemolysis</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Permanently discontinue ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td rowspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">Dermatologic Adverse Reactions </content>
                                    </content>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#LINK_23a17603-78d9-40d9-81c5-94890ee6bcaa">5.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 1</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Consider topical corticosteroids.</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 2</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <list listType="unordered" styleCode="Disc">
                                       <item>Administer topical corticosteroids.</item>
                                       <item>If not improved in ≤7 days after initiation of topical corticosteroids, administer oral corticosteroids.</item>
                                       <item>If not improved in ≤7 days after initiation of oral corticosteroids, withhold ENSACOVE until recovery to Grade ≤1.</item>
                                       <item>Resume ENSACOVE at reduced dose as per Table 1.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 3</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <list listType="unordered" styleCode="Disc">
                                       <item>Withhold ENSACOVE. Administer topical corticosteroids.</item>
                                       <item>If not improved after 7 days of initiation of topical corticosteroids, administer oral corticosteroids.</item>
                                       <item>Resume ENSACOVE at reduced dose as per Table 1 upon improvement to Grade ≤1.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 4</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue ENSACOVE.</item>
                                       <item>Administer systemic corticosteroids and consider antibiotic use.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Bradycardia </content>(HR less than 60 bpm) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_91a235ba-159d-427f-b620-887587f5c5fb">5.4</linkHtml>)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Symptomatic bradycardia</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <list listType="unordered" styleCode="Disk">
                                       <item>Withhold ENSACOVE until recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above.</item>
                                       <item>If a concomitant medication known to cause bradycardia is identified and discontinued or dose-adjusted, resume ENSACOVE at same dose upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above.</item>
                                       <item> If no concomitant medication known to cause bradycardia is identified, or if contributing concomitant medications are not discontinued or dose-adjusted, resume ENSACOVE at reduced dose as per Table 1 upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Bradycardia with life-threatening consequences, urgent intervention indicated</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue ENSACOVE if no contributing concomitant medication is identified.</item>
                                       <item>If contributing concomitant medication is identified and discontinued or dose- adjusted, resume ENSACOVE at reduced dose as per Table 1 upon recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above, with frequent monitoring as clinically indicated.</item>
                                       <item>For recurrence, permanently discontinue ENSACOVE.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Hyperglycemia </content>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#LINK_60153909-d092-4ebb-b7c1-a447d10276c2">5.5</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 3 (greater than 250 mg/dL) despite optimal anti- hyperglycemic<br/>
            therapy OR Grade 4</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <list listType="unordered" styleCode="Disc">
                                       <item>Withhold ENSACOVE until hyperglycemia is adequately controlled, then resume ENSACOVE at reduced dose as per Table 1.</item>
                                       <item>If adequate hyperglycemic control cannot be achieved with optimal medical management, permanently discontinue ENSACOVE.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Visual Disturbance</content>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_98866755-28c9-4657-b46e-54571fcbdc2b">5.6</linkHtml>)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 2 or 3</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Withhold ENSACOVE until recovery to Grade 1 or baseline, then consider resuming at reduced dose as per Table 1.</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 4</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Permanently discontinue ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Increased Creatine Phosphokinase </content>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#LINK_59f10ed4-7567-4d9b-ab6c-76e6ac786c40">5.7</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">CPK elevation greater than 5 times ULN</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disk">
                                       <item>Temporarily withhold ENSACOVE until recovery to baseline or to less than or equal to 2.5 times ULN, then resume at same dose.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">CPK elevation greater than 10 times ULN or second occurrence of CPK elevation of greater than 5 times ULN</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disk">
                                       <item>Temporarily withhold ENSACOVE until recovery to baseline or to less than or equal to 2.5 times ULN, then resume at reduced dose as per Table 1.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Hyperuricemia </content>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#LINK_05ea68c6-a1db-4fcd-8efa-c3ae8ab5040f">5.8</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Symptomatic or Grade 4</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Initiate urate-lowering medication.</item>
                                       <item>Withhold ENSACOVE until improvement of signs or symptoms.</item>
                                       <item>Resume ENSACOVE at same or reduced dose.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">Other Adverse Reactions </content>
                                    </content>
                                    <content styleCode="italics">[see Adverse Reactions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Grade 3 or 4</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold ENSACOVE until recovery to Grade 1 or baseline.</item>
                                       <item>Resume ENSACOVE at reduced dose as per Table 1.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Recurrent Grade 4</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Permanently discontinue ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Toprule">ALT = alanine aminotransferase; AST = aspartate aminotransferase; bpm = beats per minute; HR = heart rate; ULN = upper limit of normal<br/>
            *Graded per National Cancer Institute Common Terminology Criteria for Adverse Events. Version 4.03.</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2e960009-a611-4801-81a9-0a06a0dd5060">
               <id root="64f29ec7-88f1-46c8-8f04-b672ef70ae05"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>ENSACOVE capsules are available as:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>25 mg: size 2 capsule, white opaque cap and body, with “X-396” on the cap and “25 mg” on the body printed in blue ink. Each capsule contains the equivalent of 25 mg of ensartinib.</item>
                  </list>
                  <list listType="unordered" styleCode="Disc">
                     <item>100 mg: size 0 capsule, blue opaque cap and yellow opaque body, with “X-396” on the cap and “100 mg” on the body printed in white ink. Each capsule contains the equivalent of 100 mg of ensartinib.</item>
                  </list>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Capsules: 25 mg and 100 mg of ensartinib (<linkHtml href="#LINK_2e960009-a611-4801-81a9-0a06a0dd5060">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_bccf7bac-de59-4df1-a636-4a1c4f326ecc">
               <id root="36cfd819-c856-4bbe-9cb5-1ce5e62ec5fb"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ENSACOVE is contraindicated in patients who have experienced a severe hypersensitivity reaction to ENSACOVE, FD&amp;C Yellow No. 5 (tartrazine), or to any of its components <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_42288560-0f6d-4189-ba32-99b565785675">5.10</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity reaction to ENSACOVE, FD&amp;C Yellow No. 5 (tartrazine), or to any of its components. (<linkHtml href="#LINK_bccf7bac-de59-4df1-a636-4a1c4f326ecc">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_15a36c96-7ef1-49f2-b7ff-0df21df744ab">
               <id root="d240ecf8-5c37-4044-8d05-27198d5dfa35"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Interstitial Lung Disease (ILD)/Pneumonitis</content>: Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis. Permanently discontinue in patients with ILD/pneumonitis. (<linkHtml href="#LINK_921ae98f-0bfc-48a7-b789-d15f3d85ffea">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Monitor liver function tests during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity. <linkHtml href="#LINK_fdaa6fa0-f9ab-4808-8873-59eab27ec660">(5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Dermatologic Adverse Reaction</content>: Monitor for dermatologic adverse reactions during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity. (<linkHtml href="#LINK_23a17603-78d9-40d9-81c5-94890ee6bcaa">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Bradycardia</content>: Monitor heart rate regularly during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity. (<linkHtml href="#LINK_91a235ba-159d-427f-b620-887587f5c5fb">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hyperglycemia</content>: Monitor serum glucose periodically during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity. (<linkHtml href="#LINK_60153909-d092-4ebb-b7c1-a447d10276c2">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Visual Disturbances</content>: Advise patients to report visual symptoms during treatment with ENSACOVE. Withhold ENSACOVE and obtain ophthalmologic evaluation, then reduce the dose or permanently discontinue ENSACOVE. <linkHtml href="#LINK_98866755-28c9-4657-b46e-54571fcbdc2b">(5.6)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Increased Creatine Phosphokinase (CPK)</content>: Monitor CPK periodically during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity. (<linkHtml href="#LINK_15a36c96-7ef1-49f2-b7ff-0df21df744ab">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hyperuricemia</content>: Monitor uric acid periodically during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity. (<linkHtml href="#LINK_05ea68c6-a1db-4fcd-8efa-c3ae8ab5040f">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#LINK_01232394-d74e-408b-a83a-67e2aea5273e">5.9</linkHtml>)</item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_921ae98f-0bfc-48a7-b789-d15f3d85ffea">
                     <id root="cf2db820-f184-48b4-9044-4ac076741bc1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Interstitial Lung Disease/Pneumonitis</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause severe interstitial lung disease (ILD)/pneumonitis.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>ILD/pneumonitis occurred in 5% of patients treated with ENSACOVE, including Grade 3 in 1.3% and Grade 4 in 0.4%.</paragraph>
                        <paragraph>ILD/pneumonitis leading to dose interruption occurred in 0.4% and permanent discontinuation of ENSACOVE in 1.5% of patients.</paragraph>
                        <paragraph>Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, and fever) during treatment with ENSACOVE. Immediately withhold ENSACOVE in patients with suspected ILD/pneumonitis. Permanently discontinue ENSACOVE if ILD/pneumonitis is confirmed <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fdaa6fa0-f9ab-4808-8873-59eab27ec660">
                     <id root="f1454b04-b099-43ee-82ea-9d93e1df47c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Hepatotoxicity</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause hepatotoxicity including drug-induced liver injury.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>59% of patients treated with ENSACOVE had increased alanine aminotransferase (ALT), including 5% Grade 3. Increased aspartate aminotransferase (AST) occurred in 58% of patients treated with ENSACOVE, including 1.8% Grade 3. Increased bilirubin occurred in 12% of patients treated with ENSACOVE, including 2.3% Grade 3 and 0.2% Grade 4. There was one case of drug-induced liver injury in ENSACOVE-treated patients.</paragraph>
                        <paragraph>The median time to first onset of increased ALT or AST was 5.3 weeks (range: 0.4 to 152 weeks). The dose of ENSACOVE was interrupted in 4.6% of patients for increased ALT or AST. Increased ALT or AST leading to dose reduction occurred in 2.6% and permanent discontinuation of ENSACOVE in 1.1% of patients. The dose of ENSACOVE was interrupted in 1.3% of patients for increased bilirubin. Increased bilirubin leading to dose reduction occurred in 0.7% and permanent discontinuation of ENSACOVE in 1.3% of patients.</paragraph>
                        <paragraph>Monitor liver function tests including ALT, AST, and total bilirubin at baseline and every 2 weeks during the first cycle of treatment with ENSACOVE, and then monthly and as clinically indicated. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on the severity of the adverse reaction <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_23a17603-78d9-40d9-81c5-94890ee6bcaa">
                     <id root="6925e025-22f7-49db-97e0-e3068f567b0a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3 Dermatologic Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause dermatologic adverse reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), rash, pruritus, and photosensitivity.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>dermatologic adverse reactions occurred in 80% of patients receiving ENSACOVE, including Grade 3 in 14% of patients. Rash occurred in 72% of patients receiving ENSACOVE, including Grade 3 in 12% of patients. The median time to onset of rash was 9 days (range: 1 day to 17.3 months). Pruritus occurred in 32% of patients receiving ENSACOVE, with Grade 3 in 2.4%. There was one Grade 3 case (0.2%) of drug reaction with eosinophilia and systemic symptoms (DRESS).</paragraph>
                        <paragraph>The dose of ENSACOVE was interrupted in 12% of patients for dermatologic adverse reactions. Dermatologic adverse reactions leading to dose reduction occurred in 11% and permanent discontinuation of ENSACOVE in 1.5% of patients.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                              </content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">)</linkHtml>
                              </content>], </content>photosensitivity occurred in 0.9% of patients receiving ENSACOVE; all were Grade 1.</paragraph>
                        <paragraph>Monitor patients for dermatologic adverse reactions during treatment with ENSACOVE. If dermatologic adverse reactions occur, treat with antihistamine, topical or systemic steroids based on the severity. Advise patients to limit direct sun exposure while taking ENSACOVE and for at least 1 week after discontinuation. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on the severity of the adverse reaction <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_91a235ba-159d-427f-b620-887587f5c5fb">
                     <id root="199fe709-0043-4d6e-ad48-ffca17d27ad5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4 Bradycardia</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause symptomatic bradycardia.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>bradycardia (heart rate less than 60 beats per minute) occurred in 6% of patients treated with ENSACOVE. All bradycardia events were Grade 1 or 2. Bradycardia requiring dose reduction occurred in 0.2% and led to dose interruption in 0.4% of ENSACOVE-treated patients.</paragraph>
                        <paragraph>Monitor heart rate regularly during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_60153909-d092-4ebb-b7c1-a447d10276c2">
                     <id root="567d980a-86cb-4a17-9821-08b415f0b277"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 Hyperglycemia</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause hyperglycemia.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>based on laboratory data, 44% of patients receiving ENSACOVE experienced increased blood glucose, including Grade 3 in 2.5%. The median time to onset of increased blood glucose was 5.9 weeks (0.4 weeks to 3.4 years).</paragraph>
                        <paragraph>Assess fasting serum glucose at baseline and monitor serum glucose periodically during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_98866755-28c9-4657-b46e-54571fcbdc2b">
                     <id root="8992149a-3270-404b-97a2-849c2f363d62"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.6 Visual Disturbances</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause visual disturbances including blurred vision, diplopia, photopsia, vitreous floaters, visual impairment, visual field defect, and reduced visual acuity.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>8% of patients receiving ENSACOVE experienced visual disturbance, including 0.2% Grade 3. Visual disturbances led to dose interruption in 0.4% of patients.</paragraph>
                        <paragraph>Obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_59f10ed4-7567-4d9b-ab6c-76e6ac786c40">
                     <id root="e07880f7-690c-4fe4-bfc5-10c92bc404db"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.7 Increased Creatine Phosphokinase</content>
                     </title>
                     <text>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>of the 203 patients with creatine phosphokinase (CPK) laboratory data available, increased CPK occurred in 43% of patients who received ENSACOVE. The incidence of Grade 3 increased CPK was 1.5% and 0.5% were Grade</paragraph>
                        <paragraph>4. The median time to onset of increased CPK was 123 days (range: 13 days to 22 months). Increased CPK leading to dose interruption occurred in 0.2% and dose reduction in 0.4%.</paragraph>
                        <paragraph>Advise patients to report any unexplained muscle pain, tenderness, or weakness. Monitor CPK levels during treatment with ENSACOVE. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">), Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_05ea68c6-a1db-4fcd-8efa-c3ae8ab5040f">
                     <id root="c7402a58-f624-4dbd-8f09-59f1b0439324"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.8 Hyperuricemia</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause hyperuricemia.</paragraph>
                        <paragraph>In the pooled safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>based on adverse reactions, 6% of patients experienced hyperuricemia, with 0.4% Grade 3 and 0.7% Grade 4. Nine patients (1.9%) required hydration and two patients (0.4%) required urate-lowering medication.</paragraph>
                        <paragraph>Monitor serum uric acid levels prior to initiating ENSACOVE and periodically during treatment. Initiate treatment with urate-lowering medications as clinically indicated. Withhold, reduce the dose, or permanently discontinue ENSACOVE based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_012c2eae-a161-4baa-bdd8-51c043d57771">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_01232394-d74e-408b-a83a-67e2aea5273e">
                     <id root="5b53a0bf-0f6d-47ec-9d6c-5795be2dbc89"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.9 Embryo-Fetal Toxicity</content>
                     </title>
                     <text>
                        <paragraph>Based on findings from animal studies and its mechanism of action, ENSACOVE can cause fetal harm when administered to a pregnant woman. In embryo-fetal developmental studies, oral administration of ensartinib to pregnant rats during the period of organogenesis caused adverse developmental outcomes, including embryo-fetal mortality, alterations to growth, and structural abnormalities. Adverse embryo-fetal findings were seen at maternal exposures approximately equivalent to the human exposure at the recommended dose of 225 mg/day based on area under the curve (AUC). Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ENSACOVE and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ENSACOVE and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_698fa7db-1fef-42e4-b687-95e98986857b">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_8a4d65cb-3800-4c18-9fc7-66eb4e356247">8.3</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_aabbee0a-576d-4b3c-af1e-fb2e91d6b850">12.1</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_42288560-0f6d-4189-ba32-99b565785675">
                     <id root="eb9031b3-2c2f-4117-b08f-45513de05781"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.10 FD&amp;C Yellow No. 5 (Tartrazine)</content>
                     </title>
                     <text>
                        <paragraph>This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_611ede15-caab-4861-9721-cb1111fd39d2">
               <id root="ee8c2956-0f1a-4867-83f5-4c04286ff4db"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Interstitial Lung Disease/Pneumonitis <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_921ae98f-0bfc-48a7-b789-d15f3d85ffea">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hepatoxicity <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_fdaa6fa0-f9ab-4808-8873-59eab27ec660">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Dermatologic Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_23a17603-78d9-40d9-81c5-94890ee6bcaa">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Bradycardia <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_91a235ba-159d-427f-b620-887587f5c5fb">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hyperglycemia <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_60153909-d092-4ebb-b7c1-a447d10276c2">5.5</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Visual Disturbances <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_98866755-28c9-4657-b46e-54571fcbdc2b">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Increased Creatine Phosphokinase <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_59f10ed4-7567-4d9b-ab6c-76e6ac786c40">5.7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hyperuricemia <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_05ea68c6-a1db-4fcd-8efa-c3ae8ab5040f">5.8</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>FD&amp;C Yellow No. 5 (Tartrazine) <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_42288560-0f6d-4189-ba32-99b565785675">5.10</linkHtml>
                           </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_42288560-0f6d-4189-ba32-99b565785675">)</linkHtml>
                           </content>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                  </list>
                  <br/>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Most common adverse reactions (incidence ≥20%) were rash, musculoskeletal pain, constipation, pruritus, cough, nausea, edema, vomiting, fatigue, and pyrexia. (<linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>)</item>
                           <item>Most common Grade 3-4 laboratory abnormality (incidence ≥2%) were increased uric acid, decreased lymphocytes, increased alanine aminotransferase, decreased phosphate, increased gamma glutamyl transferase, increased magnesium, increased amylase, decreased sodium, increased glucose, decreased hemoglobin, increased bilirubin, decreased potassium, and increased creatine phosphokinase. (<linkHtml href="#LINK_3ab0315c-be56-4973-af2f-08210ac0db05">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Xcovery Holdings, Inc. at (866) 367-2268 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <content styleCode="underline">www.fda.gov/medwatch</content>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3ab0315c-be56-4973-af2f-08210ac0db05">
                     <id root="e4e21cbe-0d04-43c7-9e6b-4b810c81588e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to ENSACOVE as a single agent in 458 patients with locally advanced or metastatic ALK-positive NSCLC in the following trials: eXALT3 Study (N=143) <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_8a440c67-f3a4-4218-b478-6d4bcb4a8480">14.1</linkHtml>
                           </content>
                           <content styleCode="italics">
                              <linkHtml href="https://rednucleus-my.sharepoint.com/personal/cnour_rednucleus_com/Documents/Desktop/SPL/Mikes%20SPL/final-ensartinib-package-insert.docx#_bookmark50">)</linkHtml>
                           </content>
                           <content styleCode="italics">], </content>Study 101 (NCT01625234, N=98), Study BTP-28311 (NCT02959619, N=35), and</paragraph>
                        <paragraph>Study BTP-42322 (NCT03215693, N=182). Patients received ENSACOVE 225 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Among 458 patients who received ENSACOVE, 63% were exposed for 6 months or longer and 47% were exposed for greater than one year. In this pooled safety population, the most common adverse reactions (≥20%) were rash, musculoskeletal pain, constipation, pruritus, cough, nausea, edema, vomiting, fatigue, and pyrexia. The most frequent Grade 3 or 4 laboratory abnormalities (≥2%) were increased uric acid, decreased lymphocytes, increased alanine aminotransferase, decreased phosphate, increased gamma glutamyl transferase, increased magnesium, increased amylase, decreased sodium, increased glucose, decreased hemoglobin, increased bilirubin, decreased potassium, and increased creatine phosphokinase.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">TKI-naive ALK-Positive Locally Advanced or Metastatic NSCLC</content>
                           </content>
                        </paragraph>
                        <paragraph>The safety of ENSACOVE was evaluated in the eXALT3 study <content styleCode="italics">[see Clinical Studies </content>(<content styleCode="italics">
                              <linkHtml href="#LINK_8a440c67-f3a4-4218-b478-6d4bcb4a8480">14.1</linkHtml>)</content>
                           <content styleCode="italics">]. </content>Patients received ENSACOVE 225 mg orally once daily, with or without food, until disease progression or unacceptable toxicity<content styleCode="italics">. </content>Among patients who received ENSACOVE, 78% were exposed for 6 months or longer and 66% were exposed for greater than one year.</paragraph>
                        <paragraph>The median age of patients who received ENSACOVE was 54 years (range: 25-86); 50% male; 54% Asian, 43% White; 0.7% Black or African American; and 11% Hispanic or Latino.</paragraph>
                        <paragraph>Serious adverse reactions occurred in 23% of patients treated with ENSACOVE. Serious adverse reactions that occurred in ≥1% were pneumonia (4.9%), hemorrhage (2.1%), rash (2.1%) and cellulitis (1.4%). One fatal adverse reaction (0.7%) occurred due to bronchopneumonia.</paragraph>
                        <paragraph>Permanent discontinuation of ENSACOVE due to an adverse reaction occurred in 12% of patients. Adverse reactions which resulted in permanent discontinuation of ENSACOVE (≥1%) included increased ALT (2.1%), increased AST (2.1%), pneumonitis/ILD (2.1%). increased blood bilirubin (1.4%), and increased conjugated bilirubin (1.4%).</paragraph>
                        <paragraph>Dose interruptions of ENSACOVE due to an adverse reaction occurred in 41% of patients. Adverse reactions which required dose interruptions (≥2%) included rash (13%), increased ALT (6%), pneumonia (3.5%), edema (2.8%), pruritus (2.8%), pyrexia (2.8%), increased AST (2.1%),</paragraph>
                        <paragraph>hemorrhage (2.1%), and decreased appetite (2.1%).</paragraph>
                        <paragraph>Dose reductions of ENSACOVE due to an adverse reaction occurred in 24% of patients. Adverse reactions which required dose reductions (≥2%) included rash (11%), increased ALT (4.2%), pruritus (2.8%), and edema (2.1%).</paragraph>
                        <paragraph>Tables 3 and 4 summarize the most frequent adverse reactions and laboratory abnormalities, respectively.</paragraph>
                        <table width="751.8px">
                           <caption>Table 3: Adverse Reactions ( ≥10%) in Patients with ALK-Positive Locally Advanced or Metastatic NSCLC Who Received ENSACOVE in eXALT3 Study</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">ENSACOVE<br/>
                                    </content>
                                    <content styleCode="bold">N = 143</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Crizotinib</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">N = 146</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">All Grades<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Grade 3 or 4<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <content styleCode="bold">%</content> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Grade </content>
                                       <content styleCode="bold">3 or 4</content>
                                    </paragraph>
                                    <content styleCode="bold">%</content> </td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Rash<sup>a</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 66</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Pruritus<sup>b</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2.1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Alopecia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.8</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Dry Skin</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Musculoskeletal Pain<sup>c</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 36</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Cough<sup>d</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 31</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Gastrointestinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Constipation</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">31</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">26</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Nausea</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">28</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2.1</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Vomiting<sup>e</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">32</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Edema<sup>f</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2.1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">28</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2.1</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Pyrexia<sup>g</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">22</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Fatigue<sup>h</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">21</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">14</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Decreased appetite</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Infection and Infestation</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Respiratory Tract Infection</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Dizziness<sup>i</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">14</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Dysgeusia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Vascular Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Hemorrhage<sup>j</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.8</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="6"> Adverse reactions were graded using NCI CTCAE version 4.03.
            <paragraph>
                                       <sup>a </sup>Includes dermatitis, dermatitis acneiform, dermatitis bullous, drug eruption, eczema, exfoliative rash, palmar-plantar erythrodysaesthesia, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash morbilliform, rash papular, rash pruritic, rash pustular, skin exfoliation, and vulvovaginal rash</paragraph>
                                    <paragraph>
                                       <sup>b </sup>Includes ear pruritus, eye pruritus, eyelids pruritus, lip pruritus, pruritus, and pruritus generalized</paragraph>
                                    <paragraph>
                                       <sup>c </sup>Includes arthritis, spinal pain, myalgia, musculoskeletal pain, back pain, pain in extremity, neck pain, arthralgia, non-cardiac check pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort</paragraph>
                                    <paragraph>
                                       <sup>d </sup>Includes cough, productive cough, upper-airway cough syndrome</paragraph>
                                    <paragraph>
                                       <sup>e </sup>Includes vomiting and retching</paragraph>
                                    <paragraph>
                                       <sup>f </sup>Includes eyelid edema, face edema, generalized edema, localized edema, edema, edema peripheral, gravitational edema, skin edema, eye edema, and periorbital edema.</paragraph>
                                    <paragraph>
                                       <sup>g </sup>Includes pyrexia and hyperthermia</paragraph>
                                    <paragraph>
                                       <sup>h </sup>Includes fatigue and asthenia.</paragraph>
                                    <paragraph>
                                       <sup>i </sup>Includes dizziness, vertigo, postural dizziness</paragraph>
                                    <paragraph>
                                       <sup>j </sup>Includes hemoptysis, intracranial hemorrhage, gastrointestinal hemorrhage, hematuria, upper gastrointestinal hemorrhage, vaginal hemorrhage, gingival bleeding, vitreous hemorrhage, epistaxis, rectal hemorrhage, anal hemorrhage</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="755.2px">
                           <caption>Table 4: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with ALK-Positive Locally Advanced or Metastatic NSCLC Who Received ENSACOVE in eXALT3 Study</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">ENSACOVE<br/>
                                    </content>
                                    <content styleCode="bold">N = 143</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Crizotinib<br/>
                                    </content>
                                    <content styleCode="bold">N = 146</content> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Lab Abnormality</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">All Grades<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Grade 3 or 4<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">  <content styleCode="bold">All Grades<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Grade 3 or 4<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Alanine aminotransferase increased<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 73</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">74</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Alkaline phosphatase increased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">64</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2.2</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">50</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Aspartate aminotransferase increased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">64</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">62</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3.5</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Glucose increased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">49</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">35</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Albumin decreased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">46</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">56</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Phosphate decreased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">39</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">42</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.9</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Urate increased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">39</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">39</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Creatinine increased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">37</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Calcium decreased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">36</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">64</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.9</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Sodium decreased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.3</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.2</td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Lymphocytes decreased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 57</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">47</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Hemoglobin decreased</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">43</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">31</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.4</td>
                              </tr>
                              <tr>
                                 <td colspan="5">
                                    <paragraph>Adverse reactions were graded using NCI CTCAE version 4.03. </paragraph>
                                    <paragraph>ALT = Alanine aminotransferase; AST = Aspartate aminotransferase</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt;10% of patients who received ENSACOVE included interstitial lung disease, photosensitivity, increased creatinine phosphokinase, bradycardia, and visual disturbances.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5984e014-3642-4eda-ad9f-4222d98a149c">
               <id root="6ef7c2f6-96aa-41e7-bc89-cb47499d3481"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Moderate or Strong CYP3A Inhibitors</content>: Avoid concomitant use with ENSACOVE. (<linkHtml href="#LINK_dee42ab9-5ad2-40af-be74-fde836f4b6b3">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Moderate or Strong CYP3A Inducers</content>: Avoid concomitant use with ENSACOVE. (<linkHtml href="#LINK_dee42ab9-5ad2-40af-be74-fde836f4b6b3">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">P-gp Inhibitor</content>: Avoid concomitant use with ENSACOVE. (<linkHtml href="#LINK_dee42ab9-5ad2-40af-be74-fde836f4b6b3">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_dee42ab9-5ad2-40af-be74-fde836f4b6b3">
                     <id root="5287c55d-ab11-4e57-ba7a-61a5bb421e87"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 Effect of Other Drugs on ENSACOVE</content>
                     </title>
                     <text>
                        <paragraph>Table 5 describes drug interactions where concomitant use of another drug affects ENSACOVE.</paragraph>
                        <table width="799px">
                           <caption>Table 5: Effect of Other Drugs on ENSACOVE</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Strong or Moderate CYP3A Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management        </content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Avoid concomitant use of strong or moderate CYP3A inhibitors with ENSACOVE.  </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Mechanism and Clinical Effect(s)</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">This recommendation is based upon a mechanistic understanding of ensartinib  pharmacokinetics and it being a CYP3A4 substrate in vitro <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">12.3</linkHtml>
                                       </content>
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">)</linkHtml>
                                       </content>]</content>. Concomitant use with strong or moderate CYP3A inhibitors may increase ensartinib exposure; however, this has not been studied clinically.</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Strong or Moderate CYP3A Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Avoid concomitant use of strong or moderate CYP3A inducers with ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Mechanism and Clinical Effect(s)</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">This recommendation is based upon a mechanistic understanding of ensartinib pharmacokinetics and it being a CYP3A4 substrate in vitro <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">12.3</linkHtml>
                                       </content>
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">)</linkHtml>
                                       </content>]</content>. Concomitant use with strong or moderate CYP3A<br/>
            inducers may decrease ensartinib exposure; however, this has not been studied clinically.</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">P-gp Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Avoid concomitant use of P-gp inhibitors with ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Mechanism and Clinical Effect(s)</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">This recommendation is based upon a mechanistic understanding of ensartinib pharmacokinetics and it being a P-gp substrate in vitro <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">12.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>. Concomitant use with P-gp inhibitors may increase ensartinib exposure; however, this has not been studied clinically.</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="726.8px">
                           <caption>Table 5: Effect of Other Drugs on ENSACOVE</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Strong or Moderate CYP3A Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management        </content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Avoid concomitant use of strong or moderate CYP3A inhibitors with ENSACOVE.  </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Mechanism and Clinical Effect(s)</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">This recommendation is based upon a mechanistic understanding of ensartinib  pharmacokinetics and it being a CYP3A4 substrate in vitro <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">12.3</linkHtml>
                                       </content>
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">)</linkHtml>
                                       </content>]</content>. Concomitant use with strong or moderate CYP3A inhibitors may increase ensartinib exposure; however, this has not been studied clinically.</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Strong or Moderate CYP3A Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Avoid concomitant use of strong or moderate CYP3A inducers with ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Mechanism and Clinical Effect(s)</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">This recommendation is based upon a mechanistic understanding of ensartinib pharmacokinetics and it being a CYP3A4 substrate in vitro <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">12.3</linkHtml>
                                       </content>
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">)</linkHtml>
                                       </content>]</content>. Concomitant use with strong or moderate CYP3A<br/>
            inducers may decrease ensartinib exposure; however, this has not been studied clinically.</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">P-gp Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Avoid concomitant use of P-gp inhibitors with ENSACOVE.</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Mechanism and Clinical Effect(s)</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">This recommendation is based upon a mechanistic understanding of ensartinib pharmacokinetics and it being a P-gp substrate in vitro <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">12.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>. Concomitant use with P-gp inhibitors may increase ensartinib exposure; however, this has not been studied clinically.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cb485e42-9e19-431f-832f-5ebb0e94ee6c">
               <id root="3a72ed0d-0001-4173-a8cc-4184afa3fe1e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#LINK_1487aa70-63cf-417d-8947-1c5412873da2">8.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Severe Hepatic Impairment:</content> Avoid use of ENSACOVE in patients with severe hepatic impairment. <linkHtml href="#LINK_25b15809-0e35-4ab7-8862-25831ea6f21b">(8.6</linkHtml>)</item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_698fa7db-1fef-42e4-b687-95e98986857b">
                     <id root="a0cb6ff6-d87c-453f-b9d1-7d50a116b29a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on findings from animal studies and its mechanism of action <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_aabbee0a-576d-4b3c-af1e-fb2e91d6b850">12.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>, ENSACOVE can cause fetal harm when administered to a pregnant woman. There are no available data on the use of ENSACOVE in pregnant women to inform a drug-associated risk.</paragraph>
                        <paragraph>Oral administration of ensartinib to pregnant rats during the period of organogenesis caused adverse developmental outcomes, including embryo-fetal mortality, alterations to growth, and structural abnormalities. Adverse embryo-fetal findings were seen at maternal exposures approximately equivalent to the human exposure at the recommended dose of 225 mg/day based on AUC (<content styleCode="italics">see Data</content>). Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In an embryo-fetal development study, pregnant rats received 20, 40, or 80 mg/kg/day of ensartinib during the period of organogenesis (gestation day 6 to 17). Ensartinib doses ≥40 mg/kg/day (approximately equivalent to the human exposure at the recommended dose of 225 mg/day based on AUC) resulted in an increase in the incidence of fetal malformations (aortic dislocation, ventricular septal defect, separated vertebrae) and dose-dependent delayed skeletal development, including decreased or delayed ossification of the vertebrae. Ensartinib at 80 mg/kg (approximately 6.4 times the human exposure at the recommended dose of 225 mg/day based on AUC) resulted in maternal toxicity (reduced body weight and food consumption), decreased fetal body weight, increased pre- and post-implantation loss, decreases in the number of live fetuses, and visceral variations (missing renal papillae, pyelectasis).</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1487aa70-63cf-417d-8947-1c5412873da2">
                     <id root="55bb967b-6f24-402d-bb0a-ffa663908e67"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of ensartinib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with ENSACOVE and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8a4d65cb-3800-4c18-9fc7-66eb4e356247">
                     <id root="ac918be0-f23c-4a86-9d70-34bcf7d00e90"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>
                        <content styleCode="bold">8.3 Females and Males of
Reproductive Potential</content>
                     </title>
                     <text>
                        <paragraph>ENSACOVE can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_698fa7db-1fef-42e4-b687-95e98986857b">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">
                              <linkHtml href="https://rednucleus-my.sharepoint.com/personal/cnour_rednucleus_com/Documents/Desktop/SPL/Mikes%20SPL/final-ensartinib-package-insert.docx#_bookmark34">)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiating ENSACOVE. <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with ENSACOVE and for at 1 week after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENSACOVE and for 1 week after the last.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f2797901-ab74-4759-9bdc-152500329adf">
                     <id root="042c5ca6-9ad0-4048-8a82-fa2721c45475"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>The safety and effectiveness of ENSACOVE in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_261c6100-e7b3-40b7-85bf-f5f473dae1ba">
                     <id root="3adf1e2f-b219-4c9c-a806-a1e6ac2fcfb4"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Of the 458 patients enrolled in clinical studies and received ENSACOVE 225 mg once daily, 16% of the participants were aged 65 years or older. Clinical studies of ENSACOVE did not include sufficient numbers of patients ages 65 and over to determine whether they respond differently from younger patients. Exploratory analysis suggests a higher incidence of serious adverse events (43% vs 27%), more frequent adverse events leading to treatment discontinuations (18% vs 10%) and dose modifications (34% vs 16%) in patients 65 years or older as compared to those younger than 65 years.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_25b15809-0e35-4ab7-8862-25831ea6f21b">
                     <id root="23e0b58c-05dd-46f5-98cb-8d2df006716e"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>
                        <content styleCode="bold">8.6 Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>Ensartinib is primarily metabolized by the liver and patients with hepatic impairment may have increased exposures <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="https://rednucleus-my.sharepoint.com/personal/cnour_rednucleus_com/Documents/Desktop/SPL/Mikes%20SPL/final-ensartinib-package-insert.docx#_bookmark46">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]. </content>Avoid use of ENSACOVE for patients with severe hepatic impairment (total bilirubin &gt;3 times ULN and any AST) since it has not been studied in this population. Monitor patients with moderate hepatic impairment (total bilirubin</paragraph>
                        <paragraph>&gt;1.5 to ≤ 3 ULN and any AST) for increased adverse reactions and adjust ENSACOVE dosage as clinically indicated <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="https://rednucleus-my.sharepoint.com/personal/cnour_rednucleus_com/Documents/Desktop/SPL/Mikes%20SPL/final-ensartinib-package-insert.docx#_bookmark6">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">), Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="https://rednucleus-my.sharepoint.com/personal/cnour_rednucleus_com/Documents/Desktop/SPL/Mikes%20SPL/final-ensartinib-package-insert.docx#_bookmark15">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]. </content>No dosage modification is recommended for patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal (ULN) and AST &gt; ULN or total bilirubin 1 to 1.5 x ULN and any AST).</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_88ed48cc-536d-494e-bcc6-0bf5935ec7c1">
               <id root="79d3f3d6-fb9d-4e33-874b-0c11379fbc3f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ENSACOVE capsules contain ensartinib, a kinase inhibitor, present as ensartinib hydrochloride with the chemical name 6-amino-5-[(1<content styleCode="italics">R</content>)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-{4-[(3<content styleCode="italics">R</content>,5<content styleCode="italics">S</content>)- 3,5-dimethylpiperazine-1-carbonyl]phenyl}pyridazine-3-carboxamide, dihydrochloride. The molecular formula is C26H27Cl2FN6O3·2HCl and its molecular weight is 634.4 g/mol with the following structure:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>ENSACOVE capsules are intended for oral administration and are available in two dosage strengths: 25 mg ensartinib (equivalent to 28.25 mg ensartinib hydrochloride) and 100 mg ensartinib (equivalent to 113.02 mg ensartinib hydrochloride).</paragraph>
                  <paragraph>The inactive ingredients of ENSACOVE capsules are microcrystalline cellulose and stearic acid. The inactive ingredients of the 25 mg empty capsule shells are hypromellose and titanium dioxide. The inactive ingredients of the 100 mg empty capsules shells are black iron oxide, FD&amp;C Blue No. 1, FD&amp;C Yellow No. 5, hypromellose, red iron oxide, and titanium dioxide.</paragraph>
                  <paragraph>The imprinting ink for the 25 mg capsules contains butyl alcohol, dehydrated alcohol, FD&amp;C Blue No. 2, isopropyl alcohol, propylene glycol, shellac, and strong ammonia solution. The imprinting ink for the 100 mg capsules contains butyl alcohol, dehydrated alcohol, isopropyl alcohol, povidone, propylene glycol, shellac, sodium hydroxide, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ensacove-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e3c29d4d-d2d2-435f-b719-f6836d48a349">
               <id root="53c9a48f-7164-44ce-b864-b12863918127"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241226"/>
               <component>
                  <section ID="LINK_aabbee0a-576d-4b3c-af1e-fb2e91d6b850">
                     <id root="21c943cc-452a-4d54-a8f0-74d71985149a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Ensartinib is a kinase inhibitor of anaplastic lymphoma kinase (ALK) and inhibits other kinases including MET and ROS1. In vitro, ensartinib inhibited phosphorylation of ALK and its downstream signaling proteins AKT, ERK, and S6, thereby blocking ALK-mediated signaling pathways and inhibiting proliferation in cell lines harboring ALK fusions and mutations. In vivo, ensartinib showed anti-tumor activity in a mouse xenograft model of human NSCLC harboring an ALK fusion.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ae690d18-a641-43e8-918f-987f9199bdc9">
                     <id root="04b7f06d-3a44-4a60-8ea9-cc0ee6f05aa0"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Exposure-response relationship</content>
                        </paragraph>
                        <paragraph>Ensartinib exposure-response relationships and the time course of the pharmacodynamic response have not been fully characterized.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At the approved recommended dosage, a mean increase in the QTc interval &gt; 20 ms was not observed.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">
                     <id root="6ae331f4-801a-4247-b9a9-feb65197d121"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Ensartinib mean (coefficient of variation [CV%]) maximum concentration (Cmax) is 292 ng/mL (60%), and the area under the concentration-time curve (AUC0–24h) is 4,920 ng·h /ml (62%) at the approved recommended dosage. Ensartinib steady state is reached within 15 days with a mean accumulation ratio of 2.7.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Ensartinib median (minimum, maximum) time to reach Cmax (Tmax) at steady state is 3 hours (2, 8 hours).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in ensartinib pharmacokinetics were observed following administration of ENSACOVE with a high-fat meal (total 800-1000 calories, &gt; 50% fat) compared to fasted conditions.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Ensartinib mean (CV%) apparent volume of distribution is 1,720 L (42%). Ensartinib is 91.6% bound to human plasma protein.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Ensartinib mean (standard deviation [SD]) steady-state half-life (t1/2) is 30 (20) hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Ensartinib is predominantly metabolized by CYP3A.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following a single oral 200 mg dose of radiolabeled ensartinib, 91% of the radioactivity was recovered in feces (38% as unchanged) and 10% in urine (4.4% as unchanged).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of ensartinib were observed based on age (20 to 86 years), sex, race (Asian vs White), body weight (38 to 148 kg), mild to moderate renal impairment (eGFR 30 to 89 mL/min) and mild hepatic impairment (total bilirubin ≤ upper limit of normal (ULN) and AST &gt; ULN or total bilirubin 1 to 1.5 x ULN and any AST).</paragraph>
                        <paragraph>The effect of severe renal impairment (eGFR 15 to 29 mL/min), end-stage renal disease (eGFR</paragraph>
                        <paragraph>&lt;15 mL/min) with or without hemodialysis, and moderate (total bilirubin &gt;1.5 to ≤ 3 ULN and any AST) or severe (total bilirubin &gt;3 times ULN and any AST) hepatic impairment on ensartinib pharmacokinetics is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cytochrome P450 (CYP) Enzymes: </content>Ensartinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and does not induce CYP1A2, CYP2B6, or CYP3A.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Transporter Systems: </content>Ensartinib is a P-gp substrate but is not a substrate of BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1 or OCT2.</paragraph>
                        <paragraph>Ensartinib does not inhibit BCRP, P-gp, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2 or OCT3.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8e0ff5fd-5819-4d7a-b477-3aba7913c6ac">
               <id root="bee522f9-5ca7-4f2a-9d5e-547b225a3acf"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241226"/>
               <component>
                  <section ID="LINK_a6065dd2-808a-4339-b833-1ef9d3349ff9">
                     <id root="cc5cdb81-53a2-4255-b2b1-491c57385d2a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with ensartinib.</paragraph>
                        <paragraph>Ensartinib was not mutagenic in a bacterial reverse mutation (Ames) assay and was not clastogenic in an in vitro human lymphocyte chromosome aberration assay or an in vivo rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>Dedicated fertility studies were not conducted with ensartinib. No adverse effects on male or female reproductive organs were observed in up to 3-month repeat-dose toxicology studies conducted in rats and dogs.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3b95ac3a-e22f-442a-b814-8f94b19716d2">
               <id root="fd943023-008e-466f-81a3-692f996056ad"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20241226"/>
               <component>
                  <section ID="LINK_8a440c67-f3a4-4218-b478-6d4bcb4a8480">
                     <id root="610961c3-0998-4d9e-a689-cedf25ed7826"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1 TKI-naive
ALK-Positive
Locally Advanced or Metastatic NSCLC (eXALT3 Study)</content>
                     </title>
                     <text>
                        <paragraph>The efficacy of ENSACOVE was evaluated in the eXALT3 study (NCT02767804), an open- label, randomized, active-controlled, multicenter study in adult patients with locally advanced (stage IIIB following prior chemotherapy or chemoradiation or not amenable to curative intent therapy) or metastatic ALK-positive NSCLC. Patients were required to have ALK-positive NSCLC and an ECOG performance status of 0, 1, or 2. Patients could have received one prior regimen of chemotherapy but could not have previously received an ALK-targeted therapy.</paragraph>
                        <paragraph>Patients with asymptomatic, untreated brain metastases who were not on corticosteroids and patients with asymptomatic, treated brain metastases who were on stable or decreasing dose of corticosteroids were eligible. Patients were required to have completed radiation therapy at least 2 weeks, or chemotherapy at least 4 weeks, prior to enrollment. Patients with leptomeningeal disease were ineligible.</paragraph>
                        <paragraph>Patients were randomized 1:1 to receive ENSACOVE 225 mg orally once daily or crizotinib 250 mg orally twice daily in 28-day cycles until disease progression or unacceptable toxicity. Randomization was stratified by prior chemotherapy (0 vs. 1), ECOG performance status (0 or 1 vs. 2), presence of central nervous system (CNS) metastases (yes or no), and geographic region (Asia vs. the rest of the world). Tumor assessments were performed every 8 weeks.</paragraph>
                        <paragraph>The main efficacy outcome measure was progression-free survival (PFS) as evaluated by Blinded Independent Central Review (BICR) according to RECIST version 1.1. The key secondary efficacy outcome measure was overall survival (OS); other secondary outcome measures included CNS response rate, time to CNS progression, and overall response rate (ORR).</paragraph>
                        <paragraph>A total of 290 patients were randomized to ENSACOVE (n=143) or crizotinib (n=147). The baseline demographic characteristics of the overall study population were median age 54 years (range: 25-90); 16% age &gt; 65 years; 51% male; 56% Asian; 41% White and 1.4% Black; 8% Hispanic or Latino; ECOG PS 0 or 1 (95%); and 62% never smokers. Patients had Stage IIIB (8%) or Stage IV NSCLC (92%); 26% had received prior chemotherapy for advanced disease and 17% had received prior radiation. Baseline CNS metastases were present in 36% of the patients.</paragraph>
                        <paragraph>The eXALT3 study demonstrated a statistically significant improvement in PFS for patients randomized to ENSACOVE compared to patients randomized to crizotinib. The efficacy results as assessed by BICR are summarized in Table 6 and Figure 1.</paragraph>
                        <table width="635.091px">
                           <caption>Table 6: Efficacy Results for eXALT3 Study According to BICR Assessment</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Efficacy Parameter</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">ENSACOVE<br/>
                                    </content>
                                    <content styleCode="bold">N=143</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Crizotinib<br/>
                                    </content>
                                    <content styleCode="bold">N=147</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Progression-free survival</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Number of events, n (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 59 (41%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 80 (54%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Progressive disease, n (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 51 (36%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 77 (52%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Death, n (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8 (6%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 3 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Median, months (95% Cl)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">25.8 (21.8, NE)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12.7 (9.2, 16.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Hazard ratio (95% Cl)</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> 0.56 (0.40, 0.79)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      p-value<sup>a</sup>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> 0.0007</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Overall response rate</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Overall response rate % (95% Cl)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 74% (66, 81)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 67% (58, 74)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Complete response %</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5%</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Partial response %</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 62%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 61%</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Duration of response</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Number of responders, n</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 106</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 98</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Median, months (95% Cl)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NE (22.0, NE)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 27.3 (12.9, NE)</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Toprule">CI = Confidence Interval, NE=not estimable, BICR = Blinded Independent Central Review<br/>
                                    <sup>a</sup> p-value based on unstratified log-rank test</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 1 Kaplan-Meier Plot of Progression-Free Survival by IRR from Study 301 (eXALT3)</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph>At the time of the primary PFS analysis, OS results were immature. At the time of final analysis of OS, there was no statistically significant difference (p-value = 0.4570) between ENSACOVE and crizotinib. Median OS was 63.2 months in the ENSACOVE arm and 55.7 months in the crizotinib arm, with the hazard ratio of 0.88 (95% CI: 0.63, 1.23).</paragraph>
                        <paragraph> The results of the pre-specified analyses of CNS response rate by BICR in patients with baseline measurable CNS disease are summarized in Table 7.</paragraph>
                        <table width="669.636px">
                           <caption>Table 7: IRR-assessed CNS Responses in Patients with Measurable CNS Disease at Baseline in Study 301 (eXALT3)</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Efficacy Parameter</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">ENSACOVE<br/>
                                    </content>
                                    <content styleCode="bold">N=17</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">crizotinib<br/>
                                    </content>
                                    <content styleCode="bold">N=24</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">CNS overall response rate</content> % (95% Cl)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 59% (33, 82)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 21% (7, 42)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Complete response %</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8%</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Partial response %</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 35%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 13%</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Duration of Response</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Number of responders, n</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      Patients with DOR ≥ 12 months</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 30%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 40%</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Toprule">  BICR = Blinded Independent Central Review; CI = Confidence Interval</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241226"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="ensacove-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_792f24e2-c6b8-4eae-bf5e-8e7b1e6f7a7c">
               <id root="bb83e383-d1bb-4ad7-851c-46fcf9e8e06a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED</title>
               <text>
                  <paragraph>ENSACOVE (ensartinib) capsules are supplied as follows:</paragraph>
                  <table width="479px">
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Capsule Strength</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Description</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Package Configuration</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">NDC Code</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> 25 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>Size 2 capsule, white opaque cap and body, with “X-396” on the cap and “25 mg” on the body printed in blue</paragraph>
            ink.</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> Bottles of 30</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> 83076-1025-3</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> 100 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>Size 0 capsule, blue opaque cap and yellow opaque body, with “X- 396” on the cap and “100 mg” on the body</paragraph>
            printed in white ink.</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> Bottles of 60</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> 83076-1100-6</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store at controlled room temperature 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) <content styleCode="italics">[see USP Controlled Room Temperature]</content>. Store and dispense in the original bottle with desiccant to protect from moisture. Do not remove desiccant from bottle. Keep out of reach of children</paragraph>
               </text>
               <effectiveTime value="20241226"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b4e7c5f1-d326-4d38-9547-1116f32c6213">
               <id root="c6f745d6-326c-4594-9eba-d8a28e9fadd7"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information). <content styleCode="underline">Interstitial Lung Disease (ILD)/Pneumonitis</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk of severe ILD/pneumonitis during treatment with ENSACOVE. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_921ae98f-0bfc-48a7-b789-d15f3d85ffea">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatoxicity</content>
                  </paragraph>
                  <paragraph>Inform patients of the potential risk of hepatoxicity during treatment with ENSACOVE and of the need to monitor for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin elevations during treatment with ENSACOVE. Advise patients to inform their healthcare provider of any new or worsening symptoms <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_fdaa6fa0-f9ab-4808-8873-59eab27ec660">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Dermatologic Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients of the potential risk of dermatologic adverse reactions, including rash, pruritus, and photosensitivity during treatment with ENSACOVE. If dermatologic reactions occur, advise patients to limit sun exposure while taking ENSACOVE and for at least 1 week after the final dose <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_23a17603-78d9-40d9-81c5-94890ee6bcaa">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Bradycardia</content>
                  </paragraph>
                  <paragraph>Advise patients of the risk of bradycardia during treatment with ENSACOVE and to report any symptoms of bradycardia. Advise patients to inform their healthcare provider about the use of any heart or blood pressure medications during treatment with ENSACOVE <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_91a235ba-159d-427f-b620-887587f5c5fb">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hyperglycemia</content>
                  </paragraph>
                  <paragraph>Inform patients of the risks of new or worsening hyperglycemia during treatment with ENSACOVE and the need to periodically monitor glucose levels. Advise patients with diabetes mellitus or glucose intolerance that antihyperglycemic medications may need to be adjusted during treatment with ENSACOVE <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_60153909-d092-4ebb-b7c1-a447d10276c2">5.5</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Visual Disturbances</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their healthcare provider of any new or worsening vision symptoms during treatment with ENSACOVE <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_98866755-28c9-4657-b46e-54571fcbdc2b">5.6</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Creatine Phosphokinase (CPK) Elevation</content>
                  </paragraph>
                  <paragraph>Inform patients of the signs and symptoms of creatine phosphokinase (CPK) elevation and the need for monitoring during treatment with ENSACOVE. Advise patients to inform their healthcare provider of any new or worsening symptoms <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_59f10ed4-7567-4d9b-ab6c-76e6ac786c40">5.7</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hyperuricemia</content>
                  </paragraph>
                  <paragraph>Inform patients of the signs and symptoms of hyperuricemia. Advise patients to inform their healthcare provider if they experience signs or symptoms associated with hyperuricemia during treatment with ENSACOVE <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_05ea68c6-a1db-4fcd-8efa-c3ae8ab5040f">5.8</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with ENSACOVE and for 1 week after the last dose <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_01232394-d74e-408b-a83a-67e2aea5273e">5.9</linkHtml>
                     </content>
                     <content styleCode="italics">) and Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_698fa7db-1fef-42e4-b687-95e98986857b">8.1,</linkHtml>
                     </content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_8a4d65cb-3800-4c18-9fc7-66eb4e356247">8.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with ENSACOVE and for 1 week after the last dose <content styleCode="italics">[See Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_01232394-d74e-408b-a83a-67e2aea5273e">5.9</linkHtml>
                     </content>
                     <content styleCode="italics">) and Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_8a4d65cb-3800-4c18-9fc7-66eb4e356247">8.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">FD&amp;C Yellow No. 5 (tartrazine)</content>
                  </paragraph>
                  <paragraph>Advise patients that this product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type or asthma-type reactions in certain susceptible persons (e.g., patients who also have aspirin hypersensitivity) <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_42288560-0f6d-4189-ba32-99b565785675">5.10</linkHtml>
                     </content>
                     <content styleCode="italics">)</content>. Advise patients to contact their healthcare provider and seek medical help right away if they develop symptoms of an allergic reaction to FD&amp;C Yellow No. 5 (tartrazine).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with ENSACOVE and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_1487aa70-63cf-417d-8947-1c5412873da2">8.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration</content>
                  </paragraph>
                  <paragraph>Instruct patients to take ENSACOVE once a day with or without food and to swallow ENSACOVE capsules whole <content styleCode="italics">[see Dosage and Administration (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_e09e47a2-49e3-4e11-be14-178381de58a8">2.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Missed Dose</content>
                  </paragraph>
                  <paragraph>Advise patients to take ENSACOVE at the same time each day. If a dose is missed, then they should take the missed dose as soon as possible unless the next dose is due within 12 hours. Patients should be instructed not to take 2 doses at the same time to make up for a missed dose. In addition, instruct patients not to take an extra dose if they vomit after taking ENSACOVE <content styleCode="italics">[see Dosage and Administration (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_e09e47a2-49e3-4e11-be14-178381de58a8">2.2</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"> </content>
                  </paragraph>
                  <paragraph>Manufactured for: Xcovery Holdings, Inc. Miami, FL 33131</paragraph>
                  <paragraph>ENSACOVE is a trademark of Xcovery Holdings, Inc.</paragraph>
                  <paragraph>©2024, Xcovery Holdings, Inc. All rights reserved.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d7139d63-cfc4-4827-aa0c-b7906fb189f3">
               <id root="6e6e97af-60e8-4fce-8ff4-fbc8192f8228"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table width="722px">
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">PATIENT INFORMATION<br/>
                              </content>
                              <content styleCode="bold">ENSACOVE<sup>TM</sup> (En-sa-kowv)<br/>
                              </content>
                              <content styleCode="bold">(ensartinib)<br/>
                              </content>
                              <content styleCode="bold">capsules, for oral use</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">What is ENSACOVE?</content>
                              <paragraph>ENSACOVE is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene,</item>
                                 <item>that has spread to other parts of your body, and</item>
                                 <item>who have not received medicines called ALK-inhibitors.</item>
                              </list>
                              <paragraph>Your healthcare provider will perform a test to make sure that ENSACOVE is right for you.</paragraph>
            It is not known if ENSACOVE is safe and effective in children.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Do not use ENSACOVE </content>if you are allergic to ENSACOVE, FD&amp;C No. 5 (tartrazine), or to any of the ingredients in ENSACOVE. See the end of this leaflet for a complete list of ingredients in ENSACOVE.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before using ENSACOVE, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>have lung or breathing problems</item>
                                 <item>have liver problems</item>
                                 <item>have problems with your heartbeat</item>
                                 <item>have diabetes mellitus or glucose intolerance</item>
                                 <item>have problems with your vision</item>
                                 <item>are pregnant or plan to become pregnant. ENSACOVE can harm your unborn baby.
                <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider will do a pregnancy test before you start treatment with ENSACOVE.</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ENSACOVE.
                    <list listType="unordered" styleCode="Square">
                                             <item>Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENSACOVE and for 1 week after the last dose of ENSACOVE. Talk to your healthcare provider about birth control choices that are right for you during treatment with ENSACOVE.</item>
                                             <item>Males who who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ENSACOVE and for 1 week after the last dose of ENSACOVE.</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if ENSACOVE passes into your breast milk. Do not breastfeed during treatment with ENSACOVE and for 1 week after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the other medicines you take, </content>including prescription and over-the-counter medicines, vitamins and herbal supplements.</paragraph>
                              <paragraph>Certain other medicines may affect the way that ENSACOVE works and may increase your risk of certain side effects.</paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">How should I take ENSACOVE?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take ENSACOVE exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking ENSACOVE unless your healthcare provider tells you to.</item>
                                 <item>Swallow ENSACOVE capsules whole. Do not crush or chew capsules. Do not open or dissolve the contents of the capsule.</item>
                                 <item>Take ENSACOVE 1 time a day, at the same time each day.</item>
                                 <item>You may take ENSACOVE with or without food.</item>
                                 <item>If you miss a dose, take it as soon as you remember. If your next dose is due within 12 hours, skip the missed dose and take your next dose at your regular time. <content styleCode="bold">Do not </content>take 2 doses of ENSACOVE on the same day to make up for the missed dose.</item>
                                 <item>If you vomit after taking a dose of ENSACOVE, do not take an extra dose. Take your next dose at your regular time.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">What should I avoid while taking ENSACOVE?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Limit your time in the sun during treatment with ENSACOVE and for at least 1 week after your last dose. ENSACOVE may make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. When you are in the sun, wear a hat and protective clothing, and use a broad-spectrum sunscreen and lip balm with a Sun Protection Factor (SPF) of 30 or greater to protect against sunburn.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of ENSACOVE?</content>
                              <paragraph>
                                 <content styleCode="bold">ENSACOVE can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Lung problems</content>. ENSACOVE can cause severe or life-threatening swelling (inflammation) of the lungs. Symptoms may be similar to those from lung cancer. Tell your healthcare provider right away if you get any new or worsening symptoms of lung problems during treatment with ENSACOVE, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule"> 
            <list listType="unordered" styleCode="Circle">
                                 <item>trouble breathing or shortness or breath</item>
                                 <item>chest pain</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule"> 
            <list listType="unordered" styleCode="Circle">
                                 <item>cough with or without mucus</item>
                                 <item>fever</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Liver problems. </content>ENSACOVE can increase enzymes called aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and levels of bilirubin in your blood. Tell your healthcare provider if you get new or worsening signs or symptoms of liver problems, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>yellowing of your skin or the white part of your eyes</item>
                                 <item>dark or brown (tea color) urine</item>
                                 <item>nausea or vomiting</item>
                                 <item>pain on the right side of your stomach area</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>bleed or bruise more easily than normal</item>
                                 <item>itchy skin</item>
                                 <item>decreased appetite</item>
                                 <item>feeling tired</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Skin reactions. </content>ENSACOVE may cause skin reactions that require treatment. Tell your healthcare provider if you get symptoms of skin reactions, such as rash, itching, or skin swelling</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Slow heart rate (bradycardia). </content>ENSACOVE can cause very slow heartbeats that can be severe. Your healthcare provider will check your heart rate during treatment with ENSACOVE. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint during treatment with ENSACOVE. Tell your healthcare provider if you take any heart or blood pressure medicines.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">High blood sugar (hyperglycemia). </content>ENSACOVE can increase your blood sugar levels. Hyperglycemia is common with ENSACOVE treatment but can be serious. If you take medicine for diabetes or glucose intolerance your healthcare provider may change your medicine during treatment with ENSACOVE. Tell your healthcare provider if you get new or worsening signs and symptoms of hyperglycemia, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>feeling very thirsty</item>
                                 <item>needing to urinate more than usual</item>
                                 <item>feeling very hungry</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule"> 
            <list listType="unordered" styleCode="Circle">
                                 <item>feeling sick to your stomach</item>
                                 <item>feeling weak or tired</item>
                                 <item>feeling confused</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Vision problems. </content>ENSACOVE may cause vision problems. Your healthcare provider may refer you to an eye specialist if you develop new or worsening vision problems during treatment with ENSACOVE. Tell your healthcare provider if you have any loss of vision or any change in vision, including</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>blurry vision</item>
                                 <item>double vision</item>
                                 <item>seeing flashes of light</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>light hurting eyes</item>
                                 <item> new or increased floaters</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Muscle pain, tenderness, and weakness (myalgia). </content>ENSACOVE can increase the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Myalgia is common with ENSACOVE treatment but can be serious. Tell your healthcare provider if you get new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.
                </item>
                              </list>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Increased uric acid level in your blood (hyperuricemia). </content>ENSACOVE can cause too much uric acid in your blood. Hyperuricemia is common with ENSACOVE treatment but can be serious. Your healthcare provider may prescribe medicines if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule"> 
            <list listType="unordered" styleCode="Circle">
                                 <item>red, hot, tender, or swollen joints, especially your big toe</item>
                                 <item>pain in your stomach-area or sides</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule"> 
            <list listType="unordered" styleCode="Circle">
                                 <item>nausea or vomiting</item>
                                 <item>pink or brown urine</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">
                                       <content styleCode="bold">Allergic reactions to FD&amp;C Yellow No. 5 (tartrazine). </content>
                                    </content>ENSACOVE 100 mg capsules contain FD&amp;C Yellow No. 5. FD&amp;C Yellow No. 5 (tartrazine) that can cause allergic reactions in certain people, especially people who also have an allergy to aspirin. Tell your healthcare provider if you get hives, rash, or trouble breathing during treatment with ENSACOVE.</item>
                              </list>
                              <paragraph>Your healthcare provider will do certain blood tests before and during treatment with ENSACOVE to check you for side effects.</paragraph>
                              <paragraph>If you have serious side effects during treatment with ENSACOVE, your healthcare provider may change your dose, stop your treatment for a period of time (temporary), or completely stop treatment with ENSACOVE.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects </content>of ENSACOVE are:</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>rash</item>
                                 <item>muscle or bone pain</item>
                                 <item>constipation</item>
                                 <item>itching</item>
                                 <item>coughing</item>
                                 <item>nausea</item>
                                 <item>skin swelling (edema)</item>
                                 <item>vomiting</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>tiredness</item>
                                 <item>fever</item>
                                 <item>increased levels of liver and pancreatic enzymes</item>
                                 <item>decreased white blood cell counts</item>
                                 <item>changes in blood levels of phosphate, magnesium, sodium, and potassium</item>
                                 <item>decreased protein (hemoglobin) in red blood cells</item>
                                 <item>increased bilirubin blood levels</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule"> These are not all the possible side effects with ENSACOVE.<br/>
            Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">How should I store ENSACOVE?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store ENSACOVE at room temperature between 68ºF to 77ºF (20ºC to 25ºC).</item>
                                 <item>Keep ENSACOVE capsules in the original bottle.</item>
                                 <item>The bottle of ENSACOVE capsules contains a drying agent (desiccant) to help keep your medicine dry. Do not remove the desiccant from the bottle after opening. Do not open or eat the desiccant.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep ENSACOVE and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of ENSACOVE.</content>
                              <br/>
            Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ENSACOVE for a condition for which it was not prescribed. Do not give ENSACOVE to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ENSACOVE that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in ENSACOVE?</content>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> ensartinib hydrochloride</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> butyl alcohol, dehydrated alcohol, hypromellose, isopropyl alcohol, microcrystalline cellulose, propylene glycol, shellac, stearic acid, and titanium dioxide. The 25 mg capsules also contain the following inactive ingredients: FD&amp;C Blue No. 2 and strong ammonia solution. The 100 mg capsules also contain the following inactive ingredients: black iron oxide, FD&amp;C Blue No. 1, FD&amp;C Yellow No. 5, povidone, red iron oxide, and sodium hydroxide.</paragraph>
                              <paragraph>Manufactured for: Xcovery Holdings, Inc., Miami, FL, 33131<br/>
            ENSACOVE is a trademark of Xcovery Holdings, Inc.<br/>
            ©2024, Xcovery Holdings, Inc. All rights reserved.</paragraph>
            For more information, call Xcovery Holdings, Inc. at (866) 367-2268.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">This Patient Information has been approved by the U.S. Food and Drug Administration</td>
                           <td align="right"> Issued: 12/2024</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section ID="LINK_29457f43-820d-4273-bc5e-825ed68b9a6f">
               <id root="b76387d1-e452-475e-bea9-0f16a0f7a84e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 25 mg</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">ENSACOVE<sup>™</sup> (ensartinib) capsules - 25 mg</content>
                  </paragraph>
                  <paragraph>Bottle of 30 Capsules</paragraph>
                  <paragraph>NDC 83076-1025-3</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20241226"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>25 mg Bottle label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ensacove-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>25mg Carton Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ensacove-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e1cc3080-7535-4e9a-acf8-0385da71b150">
               <id root="5ca22905-df4f-4cb3-8364-321d220ac918"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">ENSACOVE<sup>™</sup> (ensartinib) capsules - 100 mg</content>
                  </paragraph>
                  <paragraph>Bottle of 60 Capsules</paragraph>
                  <paragraph>NDC 83076-1100-6</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20241226"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>100 mg bottle label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ensacove-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>100mg Carton Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ensacove-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>